Momenta Pharmaceuticals CEO Craig Wheeler: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
This article was originally published in The Pink Sheet Daily
Exec discusses follow-on biologic legislation and Momenta’s pipeline.
You may also be interested in...
Exec outlines the company's efforts to get generic of Sanofi-Aventis' Lovenox to market, its partnership with Sandoz involving biogenerics and other business strategy initiatives.
At Senate hearing, co-author of ANDA legislation says that FDA should require clinical trials from sponsors seeking follow-on biologic approval.
CEO Clozel discusses the firm’s renin inhibitor program in the face of Novartis’ Tekturna, alliances with Merck and Roche and its business strategy going forward.